Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 89.5%

Neg 0% Neu 0% Pos 89.5%

Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.